JP2017510297A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510297A5 JP2017510297A5 JP2017501087A JP2017501087A JP2017510297A5 JP 2017510297 A5 JP2017510297 A5 JP 2017510297A5 JP 2017501087 A JP2017501087 A JP 2017501087A JP 2017501087 A JP2017501087 A JP 2017501087A JP 2017510297 A5 JP2017510297 A5 JP 2017510297A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- chimeric nucleic
- immunization composition
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004707 nucleic acids Proteins 0.000 claims description 113
- 102000039446 nucleic acids Human genes 0.000 claims description 113
- 150000007523 nucleic acids Chemical class 0.000 claims description 113
- 230000003053 immunization Effects 0.000 claims description 68
- 239000000427 antigen Substances 0.000 claims description 66
- 108091007433 antigens Proteins 0.000 claims description 66
- 102000036639 antigens Human genes 0.000 claims description 66
- 238000002649 immunization Methods 0.000 claims description 64
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 31
- 230000000890 antigenic effect Effects 0.000 claims description 23
- 239000013598 vector Substances 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 241000588724 Escherichia coli Species 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 230000001717 pathogenic effect Effects 0.000 claims description 10
- 244000052769 pathogen Species 0.000 claims description 8
- 230000014621 translational initiation Effects 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 241000712461 unidentified influenza virus Species 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 238000009175 antibody therapy Methods 0.000 claims description 5
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 241000214054 Equine rhinitis A virus Species 0.000 claims description 4
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 4
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims description 4
- 102100024028 Progonadoliberin-1 Human genes 0.000 claims description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 4
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 4
- 102100022748 Wilms tumor protein Human genes 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 4
- 125000006850 spacer group Chemical group 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 102000010451 Folate receptor alpha Human genes 0.000 claims description 3
- 108050001931 Folate receptor alpha Proteins 0.000 claims description 3
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- -1 cosmid Substances 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 206010022000 influenza Diseases 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 241000710929 Alphavirus Species 0.000 claims description 2
- 241000271566 Aves Species 0.000 claims description 2
- 108700020463 BRCA1 Proteins 0.000 claims description 2
- 102000036365 BRCA1 Human genes 0.000 claims description 2
- 101150072950 BRCA1 gene Proteins 0.000 claims description 2
- 102000052609 BRCA2 Human genes 0.000 claims description 2
- 108700020462 BRCA2 Proteins 0.000 claims description 2
- 241000193738 Bacillus anthracis Species 0.000 claims description 2
- 101150008921 Brca2 gene Proteins 0.000 claims description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 2
- 108020004638 Circular DNA Proteins 0.000 claims description 2
- 108091028075 Circular RNA Proteins 0.000 claims description 2
- 241000193155 Clostridium botulinum Species 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- 241001115402 Ebolavirus Species 0.000 claims description 2
- 241000710831 Flavivirus Species 0.000 claims description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 2
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims description 2
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 241000186779 Listeria monocytogenes Species 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 claims description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 2
- 241000714209 Norwalk virus Species 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229940124060 PD-1 antagonist Drugs 0.000 claims description 2
- 108091007960 PI3Ks Proteins 0.000 claims description 2
- 241000709664 Picornaviridae Species 0.000 claims description 2
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 241000125945 Protoparvovirus Species 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 241000702263 Reovirus sp. Species 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 2
- 241000713675 Spumavirus Species 0.000 claims description 2
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 241000700647 Variola virus Species 0.000 claims description 2
- 101710127857 Wilms tumor protein Proteins 0.000 claims description 2
- 241000607479 Yersinia pestis Species 0.000 claims description 2
- 206010064097 avian influenza Diseases 0.000 claims description 2
- 229940065181 bacillus anthracis Drugs 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 244000045947 parasite Species 0.000 claims description 2
- 229960002087 pertuzumab Drugs 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims 24
- 108020001507 fusion proteins Proteins 0.000 claims 24
- 229920001184 polypeptide Polymers 0.000 claims 6
- 101100281008 Homo sapiens FGF2 gene Proteins 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 238000011144 upstream manufacturing Methods 0.000 claims 3
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 claims 2
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 241000194017 Streptococcus Species 0.000 claims 2
- 241001648840 Thosea asigna virus Species 0.000 claims 2
- 238000002650 immunosuppressive therapy Methods 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000030648 nucleus localization Effects 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 102000006311 Cyclin D1 Human genes 0.000 claims 1
- 108010058546 Cyclin D1 Proteins 0.000 claims 1
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 102000038030 PI3Ks Human genes 0.000 claims 1
- 230000003432 anti-folate effect Effects 0.000 claims 1
- 229940127074 antifolate Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 229950009929 farletuzumab Drugs 0.000 claims 1
- 239000004052 folic acid antagonist Substances 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 102000051957 human ERBB2 Human genes 0.000 claims 1
- 102000053180 human FOLR1 Human genes 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000010189 intracellular transport Effects 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 43
- 230000024932 T cell mediated immunity Effects 0.000 description 8
- 238000009098 adjuvant therapy Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 102100028281 ABC-type oligopeptide transporter ABCB9 Human genes 0.000 description 1
- 101710192090 ABC-type oligopeptide transporter ABCB9 Proteins 0.000 description 1
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 description 1
- 102100030343 Antigen peptide transporter 2 Human genes 0.000 description 1
- 102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 description 1
- 102000009073 Macrophage Migration-Inhibitory Factors Human genes 0.000 description 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 101800000849 Tachykinin-associated peptide 2 Proteins 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461954588P | 2014-03-17 | 2014-03-17 | |
| US61/954,588 | 2014-03-17 | ||
| PCT/US2015/021117 WO2015142963A1 (en) | 2014-03-17 | 2015-03-17 | Nucleic acid molecule vaccine compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019168454A Division JP2019205482A (ja) | 2014-03-17 | 2019-09-17 | 核酸分子ワクチン組成物およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017510297A JP2017510297A (ja) | 2017-04-13 |
| JP2017510297A5 true JP2017510297A5 (https=) | 2018-04-26 |
Family
ID=52774612
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017501087A Pending JP2017510297A (ja) | 2014-03-17 | 2015-03-17 | 核酸分子ワクチン組成物およびその使用 |
| JP2019168454A Pending JP2019205482A (ja) | 2014-03-17 | 2019-09-17 | 核酸分子ワクチン組成物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019168454A Pending JP2019205482A (ja) | 2014-03-17 | 2019-09-17 | 核酸分子ワクチン組成物およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (8) | US9364523B2 (https=) |
| EP (1) | EP3119893A1 (https=) |
| JP (2) | JP2017510297A (https=) |
| CN (1) | CN106459992A (https=) |
| AU (2) | AU2015231461B2 (https=) |
| BR (1) | BR112016021345A8 (https=) |
| CA (1) | CA2942501A1 (https=) |
| WO (1) | WO2015142963A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016184822A1 (en) | 2015-05-15 | 2016-11-24 | Curevac Ag | Prime-boost regimens involving administration of at least one mrna construct |
| SMT202200370T1 (it) | 2015-11-20 | 2022-11-18 | Memorial Sloan Kettering Cancer Center | Composizione per il trattamento del cancro |
| EP3452082A1 (en) | 2016-05-04 | 2019-03-13 | Fred Hutchinson Cancer Research Center | Cell-based neoantigen vaccines and uses thereof |
| US10835596B2 (en) | 2016-07-15 | 2020-11-17 | Etubics Corporation | Compositions and methods for flavivirus vaccination |
| JP6903120B2 (ja) * | 2016-07-15 | 2021-07-14 | エトゥビクス コーポレーション | アルファウイルスワクチン接種のための組成物及び方法 |
| CA3044424C (en) * | 2016-11-21 | 2023-05-23 | Nant Holdings Ip, Llc | Fractal combination therapy |
| BR112019015797A2 (pt) | 2017-02-01 | 2020-03-17 | Modernatx, Inc. | Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação |
| CN111065400A (zh) * | 2017-10-03 | 2020-04-24 | 公益财团法人东京都医学总合研究所 | 抗流感药物 |
| EP3727468A4 (en) | 2017-12-19 | 2021-09-22 | Akouos, Inc. | AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR |
| CN110117675B (zh) * | 2018-02-05 | 2022-03-04 | 西比曼生物科技（香港）有限公司 | 一种实时荧光定量pcr检测rcl的试剂和方法 |
| CN108619499A (zh) * | 2018-04-17 | 2018-10-09 | 南昌大学 | 一种结核病疫苗及其制备工艺 |
| CN110144334B (zh) * | 2019-05-05 | 2021-03-16 | 中国水产科学研究院长江水产研究所 | 一种共表达草鱼呼肠孤病毒外衣壳蛋白vp4和vp35的重组杆状病毒的制备方法和应用 |
| IL293012A (en) * | 2019-11-20 | 2022-07-01 | Bavarian Nordic As | Medicinal uses of 4-1bbl modified ankara virus vaccinia ((recombinant mva |
| BR112022015565A2 (pt) * | 2020-02-07 | 2022-09-27 | Modernatx Inc | Vacinas de domínio de mrna para sars-cov-2 |
| CN111330002B (zh) * | 2020-03-09 | 2020-12-01 | 北京鼎成肽源生物技术有限公司 | 靶向冠状病毒的通用dc细胞疫苗及其制备方法和应用 |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| US6028058A (en) * | 1997-07-21 | 2000-02-22 | Ciblex Corporation | Methods and compositions for regulating nuclear trafficking of proteins |
| US6709863B2 (en) | 1999-12-08 | 2004-03-23 | Iowa State University Research Foundation | Nucleic acid molecules encoding multiple start codons and histidine tags |
| US20110111413A1 (en) | 2001-02-02 | 2011-05-12 | Padgett Hal S | Method of optimizing codon usage through dna shuffling |
| CA2500955A1 (en) | 2002-10-03 | 2004-04-15 | Genencor International, Inc. | Optimized multi-epitope constructs and uses thereof |
| CA2685300C (en) | 2006-06-01 | 2017-01-03 | Mayo Foundation For Medical Education And Research | Immunity to folate receptors |
| CA2673757A1 (en) | 2006-11-30 | 2008-06-05 | Tapimmune Inc. | Poxviridae treatment |
| US20080292918A1 (en) | 2007-05-25 | 2008-11-27 | Caine Finnerty | Electrochemical system having multiple independent circuits |
| JP2011502484A (ja) | 2007-11-01 | 2011-01-27 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | Ｈｌａ−ｄｒ結合性ペプチドおよびそれらの使用 |
| US8858952B2 (en) * | 2009-02-19 | 2014-10-14 | Mayo Foundation For Medical Education And Research | Methods and materials for generating T cells |
| EP2545071A2 (en) | 2010-03-09 | 2013-01-16 | Maksyutov, Amir | Polyepitope constructs and methods for their preparation and use |
| WO2015063647A1 (en) | 2013-11-01 | 2015-05-07 | Pfizer Inc. | Vectors for expression of prostate-associated antigens |
-
2015
- 2015-03-17 CA CA2942501A patent/CA2942501A1/en active Pending
- 2015-03-17 US US14/660,924 patent/US9364523B2/en not_active Expired - Fee Related
- 2015-03-17 JP JP2017501087A patent/JP2017510297A/ja active Pending
- 2015-03-17 AU AU2015231461A patent/AU2015231461B2/en not_active Ceased
- 2015-03-17 CN CN201580023035.XA patent/CN106459992A/zh active Pending
- 2015-03-17 WO PCT/US2015/021117 patent/WO2015142963A1/en not_active Ceased
- 2015-03-17 BR BR112016021345A patent/BR112016021345A8/pt not_active Application Discontinuation
- 2015-03-17 EP EP15713123.6A patent/EP3119893A1/en not_active Withdrawn
-
2016
- 2016-06-13 US US15/180,852 patent/US9988643B2/en not_active Expired - Fee Related
- 2016-07-28 US US15/222,619 patent/US9655956B2/en not_active Expired - Fee Related
- 2016-07-28 US US15/222,627 patent/US10030252B2/en active Active
-
2018
- 2018-01-29 US US15/882,724 patent/US20180163226A1/en not_active Abandoned
- 2018-01-29 US US15/882,626 patent/US20180230487A1/en not_active Abandoned
-
2019
- 2019-09-17 JP JP2019168454A patent/JP2019205482A/ja active Pending
-
2021
- 2021-03-01 US US17/189,120 patent/US20220033844A1/en not_active Abandoned
- 2021-04-05 US US17/222,910 patent/US20220056473A1/en not_active Abandoned
- 2021-12-08 AU AU2021282438A patent/AU2021282438A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017510297A5 (https=) | ||
| JP6768045B2 (ja) | ワクチン接種とｐｄ−１経路の阻害との組み合わせ | |
| Liu et al. | mRNA cancer vaccines: construction and boosting strategies | |
| US20240101608A1 (en) | Optimized nucleic acid molecules | |
| Tondini et al. | A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control | |
| US20220056473A1 (en) | Chimeric nucleic acid molecules with non-aug translation initiation sequences and uses thereof | |
| CA2935878A1 (en) | Combination of vaccination and ox40 agonists | |
| EP2958588A1 (en) | Combination of vaccination and inhibition of the pd-1 pathway | |
| Srivastava et al. | Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner | |
| JP2014534807A (ja) | クロスプレゼンテーションを行う樹状細胞を標的としたワクチボディ | |
| Li et al. | mRNA vaccines: current applications and future directions | |
| JP2018100243A5 (https=) | ||
| Ray et al. | Altering landscape of cancer vaccines: unique platforms, research on therapeutic applications and recent patents | |
| JP2020526202A5 (https=) | ||
| Meisel et al. | mRNA vaccines against infectious diseases and cancer | |
| JP2019509275A (ja) | マルチゲノムレトロウイルスベクター調製物ならびにそれらを産生および使用するための方法およびシステム | |
| Ratre et al. | Molecular farming and anticancer vaccine: current opportunities and openings | |
| Werninghaus et al. | A combinatorial DNA vaccine encoding APC-targeted, bivalent HA and NA antigens results in an improved influenza vaccine | |
| Wang et al. | Modulatory effects of tumor-derived heat shock protein in DNA vaccination against nasopharyngeal carcinoma | |
| Xiang | Synergistic DNA+ Adenovirus Prime-Boost Immunization in Metastatic Colorectal Cancer | |
| Aldrich | A mechanistic analysis of DNA vaccine-induced tumor immunity against the viral oncoprotein simian virus 40 large tumor antigen |